<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220702055335N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-17</date_registration>
      <primary_sponsor>Vice chancellor for Research,Tabriz University Of Medical Sciences</primary_sponsor>
      <public_title>Evaluating the role of hysteroscopy in the success of  In vitro fertilization (IVF)</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the role of hysteroscopy in the success of in vitro fertilization (IVF)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-17</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>130</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70790</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: People will be allocated to two intervention and control groups by the method of balanced block randomization.The number of blocks is 33 and the volume inside each block is 4.  The order in which the participants enter the study groups determines the order within each group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Female infertility.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group, 1 to 3 months before the start of IVF, hysteroscopy is first performed by a surgeon in the early to mid-follicular phase of the menstrual cycle.Ovulation stimulation is done with Letrozole, Sinal F, hMG and Sterotide.  When at least two to three follicles of 18 mm are seen in the ultrasound, the release of eggs is done by decapeptyl and hCG.At most one or two cycles after ovulation, from the second day of the menstrual cycle, the preparation of the endometrium for embryo transfer is done using HRT and estrogen and progesterone, and a maximum of 2 to 3 3-day-old embryos (cleavage) are transferred as Freez.The luteal phase is supported with progesterone ampoules and suppositories until the end of the first trimester. Intervention 2: In the control group, two 2.5 mg letrozole tablets are given daily from the third day of menstruation until the day of hCG injection.  From the third day of starting letrozole, 150 to 300 units of Sinal F ampoules are given daily until the day of hCG injection.From the second day of SinalF injection, one or two hMG is given daily until the day of hCG injection, and when the first follicle reaches 14 mm in size, one Sterotide 250 is given daily.When at least 2 to 3 18 mm follicles are detected in ultrasound, egg release is done by 10,000 units of Hcg and two ampoules of 0.1 decapeptyl, and 36 hours later, ovulation is done by vaginal ultrasound.At most one to two cycles after the second day of the menstrual cycle, 6 mg of estradiol per day is started for the patient, and when the endometrial thickness reaches at least 7 to 8 mm, 50-100 mg of intramuscular progesterone is given to the patient for 4 days. It will be given and on the fourth day of progesterone injection, transfer of 2 to 3 three-day-old embryos (cleavage) is performed for the patient.Luteal phase support is done until the end of the third month with progesterone 50mg ampoules every other day and progesterone 400 suppositories every 12 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is After the completion of the project, the decision will be made.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Parvin Hakimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tabriz University Of Medical Sciences, Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5138665793</zip>
        <telephone>+98 41 3551 9161</telephone>
        <email>lahroudin@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Parvin Hakimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tabriz University Of Medical Sciences, Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5138665793</zip>
        <telephone>+98 35519161</telephone>
        <email>lahroudin@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Primary infertility
Age below 40 years
Body mass index between 19 and 35 kg/m2
Couples who have not had any identifiable reason for infertility after one year of infertility investigation
Hysterosalpingography based on open uterine tubes
The number of antral follicles, bigger and equal 5</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Azoospermia
The History of Surgical Treatment of Endometrial
History of in vitro fertilisation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Female infertility, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group, 1 to 3 months before the start of IVF, hysteroscopy is first performed by a surgeon in the early to mid-follicular phase of the menstrual cycle.Ovulation stimulation is done with Letrozole, Sinal F, hMG and Sterotide.  When at least two to three follicles of 18 mm are seen in the ultrasound, the release of eggs is done by decapeptyl and hCG.At most one or two cycles after ovulation, from the second day of the menstrual cycle, the preparation of the endometrium for embryo transfer is done using HRT and estrogen and progesterone, and a maximum of 2 to 3 3-day-old embryos (cleavage) are transferred as Freez.The luteal phase is supported with progesterone ampoules and suppositories until the end of the first trimester</i_keyword>
      <i_keyword>In the control group, two 2.5 mg letrozole tablets are given daily from the third day of menstruation until the day of hCG injection.  From the third day of starting letrozole, 150 to 300 units of Sinal F ampoules are given daily until the day of hCG injection.From the second day of SinalF injection, one or two hMG is given daily until the day of hCG injection, and when the first follicle reaches 14 mm in size, one Sterotide 250 is given daily.When at least 2 to 3 18 mm follicles are detected in ultrasound, egg release is done by 10,000 units of Hcg and two ampoules of 0.1 decapeptyl, and 36 hours later, ovulation is done by vaginal ultrasound.At most one to two cycles after the second day of the menstrual cycle, 6 mg of estradiol per day is started for the patient, and when the endometrial thickness reaches at least 7 to 8 mm, 50-100 mg of intramuscular progesterone is given to the patient for 4 days. It will be given and on the fourth day of progesterone injection, transfer of 2 to 3 three-day-old embryos (cleavage) is performed for the patient.Luteal phase support is done until the end of the third month with progesterone 50mg ampoules every other day and progesterone 400 suppositories every 12 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Chemical pregnancy rate. Timepoint: Two week after transfer. Method of measurement: BHCG≥200.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Clinical pregnancy rate. Timepoint: Two week after transfer. Method of measurement: Observation of pregnancy sac and Fetal Heart in ultrasonography.</sec_outcome>
      <sec_outcome>Rate of abortion. Timepoint: Until the 20th week of pregnancy. Method of measurement: The observation of bleeding.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for Research,Tabriz University Of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-02</approval_date>
        <contact_name>Ethics Committee Of Tabriz University Of Medical Sciences</contact_name>
        <contact_address>Third Floor, Central Building of Number2, Golgasht Street Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
